AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery ...

About a year ago, [Scott] completed what is probably one of the finest builds ever shown on a YouTube channel. It was an expanding wooden table, a build inspired by a fantastically expensive expanding ...

Whether you’re looking to add some excitement to your basement entertaining area or elevate your game room setup, a pool table is a great way to bring people together for some friendly competition.

Camping tents and sleeping bags may get the glory, but your camping table is arguably the MVP of any camping trip. That’s because it’s the glue that ties together the best camp kitchens, acting as the ...

As Chief Editor of one of the two journals in which Biopharma Dealmakers appears, I have a keen interest in the process of translating biomedical research into new drugs, including the partnerships ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

Google Tables, a work-tracking tool and competitor to the popular spreadsheet-database hybrid Airtable, is shutting down. In an email sent to Tables users this week, Google said the app will not be ...

(RTTNews) - AbbVie (ABBV) has completed its acquisition of Capstan Therapeutics, bringing the biotech company under its umbrella. Capstan's lead program, CPTX2309, is a Phase 1 tLNP-based therapy that ...

NORTH CHICAGO - AbbVie (NYSE:ABBV), a $365 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Tuesday it has completed its acquisition of Capstan Therapeutics, ...

Capstan Therapeutics — a biotechnology company pioneered by Penn researchers — was acquired by AbbVie in $2.1 billion deal. Capstan, which specializes in CAR-T therapies for autoimmune disorders, ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up ...